HC Wainwright Has Negative Outlook for CRNX FY2025 Earnings

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) – Stock analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Crinetics Pharmaceuticals in a note issued to investors on Sunday, December 14th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($5.04) per share for the year, down from their previous forecast of ($5.01). The consensus estimate for Crinetics Pharmaceuticals’ current full-year earnings is ($3.73) per share. HC Wainwright also issued estimates for Crinetics Pharmaceuticals’ Q4 2025 earnings at ($1.38) EPS, Q1 2026 earnings at ($1.35) EPS, Q2 2026 earnings at ($1.37) EPS, Q3 2026 earnings at ($1.40) EPS, FY2026 earnings at ($5.55) EPS and FY2027 earnings at ($3.59) EPS.

Several other equities analysts have also commented on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Crinetics Pharmaceuticals from $53.00 to $52.00 and set an “overweight” rating on the stock in a report on Wednesday, September 24th. Robert W. Baird upped their price target on Crinetics Pharmaceuticals from $58.00 to $62.00 and gave the stock an “outperform” rating in a research note on Friday, September 26th. Morgan Stanley raised their price target on Crinetics Pharmaceuticals from $65.00 to $77.00 and gave the stock an “overweight” rating in a research report on Monday, September 29th. The Goldman Sachs Group boosted their price objective on Crinetics Pharmaceuticals from $35.00 to $40.00 and gave the company a “neutral” rating in a report on Friday, September 26th. Finally, Citizens Jmp lowered their target price on Crinetics Pharmaceuticals from $143.00 to $108.00 and set a “market outperform” rating for the company in a report on Friday, November 7th. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $77.55.

Crinetics Pharmaceuticals Price Performance

Shares of CRNX stock opened at $45.14 on Wednesday. Crinetics Pharmaceuticals has a 1-year low of $24.10 and a 1-year high of $54.78. The firm has a market cap of $4.28 billion, a PE ratio of -9.96 and a beta of 0.20. The company has a 50-day moving average of $44.25 and a two-hundred day moving average of $36.63.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.11). The company had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.39 million. During the same period last year, the firm earned ($0.96) earnings per share.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its position in shares of Crinetics Pharmaceuticals by 279.2% during the third quarter. JPMorgan Chase & Co. now owns 1,258,722 shares of the company’s stock worth $52,426,000 after purchasing an additional 926,765 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new position in Crinetics Pharmaceuticals during the third quarter worth approximately $401,000. CANADA LIFE ASSURANCE Co increased its position in Crinetics Pharmaceuticals by 17.4% during the third quarter. CANADA LIFE ASSURANCE Co now owns 22,561 shares of the company’s stock worth $981,000 after buying an additional 3,342 shares during the period. Dark Forest Capital Management LP purchased a new stake in Crinetics Pharmaceuticals in the third quarter valued at approximately $213,000. Finally, Paradigm Biocapital Advisors LP boosted its holdings in shares of Crinetics Pharmaceuticals by 8.8% in the third quarter. Paradigm Biocapital Advisors LP now owns 2,550,774 shares of the company’s stock valued at $106,240,000 after acquiring an additional 207,221 shares during the period. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Insider Buying and Selling

In related news, insider Dana Pizzuti sold 5,000 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $42.66, for a total value of $213,300.00. Following the transaction, the insider owned 66,270 shares of the company’s stock, valued at $2,827,078.20. This represents a 7.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Richard Scott Struthers sold 4,000 shares of the stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $45.00, for a total value of $180,000.00. Following the completion of the transaction, the chief executive officer owned 106,000 shares in the company, valued at approximately $4,770,000. The trade was a 3.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 30,000 shares of company stock worth $1,318,350. Corporate insiders own 4.60% of the company’s stock.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.